Waive COVID-19 vaccine patents, say top UK scientists

12 July 2021
vaccines_large-1-

Leading UK scientists have warned the government that patent protections on COVID-19 vaccines threaten the security of the country’s vaccination program and could lead to further lockdowns after July 19, when restrictions are currently due to lift.

Stephen Reicher, who advises the government’s SAGE group of scientists, and Christina Pagel, a member of Independent SAGE, have warned that the government risks producing variants instead of vaccines by upholding intellectual property rules on the jabs.

The scientists warn that allowing the virus to spread in poorer countries could lead to new variants of COVID-19 that are more virulent or resistant to vaccines, derailing the UK’s vaccine programs, forcing Prime Minister Boris Johnson and the government to reintroduce lockdown restrictions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical